{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:09:49Z","timestamp":1794852589462,"version":"4.9.1"},"reference-count":131,"publisher":"Bentham Science Publishers Ltd.","issue":"7","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["COS"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>There has been a growing body of studies on benzothiazoles and benzothiazole derivatives\nas strong and effective anti-tumor agents against lung, liver, pancreas, breast, and brain\ntumors. Due to the highly proliferative nature of the tumor cells, the oxygen levels get lower than\nthat of normal tissues in the tumor microenvironment. This situation is called hypoxia and has\nbeen associated with increased ability for carcinogenesis. For the drug design and development\nstrategies, the hypoxic nature of the tumor tissues has been exploited more aggressively. Hypoxia\nitself acts as a signal initiating system to activate the pathways that eventually lead to the spread\nof the tumor cells into the different tissues, increases the rate of DNA damage, and eventually\nends up with more mutation levels that may increase the drug resistance. As one of the major\nmediators of hypoxic response, hypoxia-inducible factors (HIFs) have been shown to activate\nangiogenesis, metastasis, apoptosis resistance, and many other protumorigenic responses in cancer\ndevelopment. In the current review, we will be discussing the design, synthesis, and structureactivity\nrelationships of benzothiazole derivatives against hypoxic tumors such as lung, liver,\npancreas, breast, and brain as potential anti-cancer drug candidates. The focus points of the study\nwill be the biology behind carcinogenesis and how hypoxia contributes to the process, recent\nstudies on benzothiazole and its derivatives as anti-cancer agents against hypoxic cancers, conclusions,\nand future perspectives. We believe that this review will be useful for researchers in the\nfield of drug design during their studies to generate novel benzothiazole-containing hybrids\nagainst hypoxic tumors with higher efficacies.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570179419666220330001036","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T09:18:28Z","timestamp":1648631908000},"page":"772-796","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A Review on the Design, Synthesis, and Structure-activity Relationships of\nBenzothiazole Derivatives against Hypoxic Tumors"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5986-8248","authenticated-orcid":true,"given":"Yahya","family":"Nural","sequence":"first","affiliation":[{"name":"Department of Analytical Chemistry, Faculty of Pharmacy, Mersin University,\nMersin, 33169, Turkey"},{"name":"Advanced Technology, Research and Application Center, Mersin University, 33343 Mersin,\nTurkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akif Hakan","family":"Kurt","sequence":"additional","affiliation":[{"name":"Department of Medicinal Pharmacology, Faculty of Medicine, Bolu Abant \u0130zzet Baysal University, 14030, Bolu, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lokman","family":"Ayaz","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Pharmacy, Trakya University, Edirne, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furkan","family":"Ayaz","sequence":"additional","affiliation":[{"name":"Department of Biotechnology,\nFaculty of Arts and Science, Mersin University, Mersin 33343, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynel","family":"Seferoglu","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Faculty of Science, Gazi University, TR-06560, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.7150\/jca.10336","volume":"6","author":"Di Lonardo A.","year":"2015","unstructured":"Di Lonardo A.; Nasi S.; Pulciani S.; Cancer: We should not forget the past. J Cancer 2015,6(1),29-39","journal-title":"J Cancer"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"Bray F.","year":"2018","unstructured":"Bray F.; Ferlay J.; Soerjomataram I.; Siegel R.L.; Torre L.A.; Jemal A.; Global cancer statistics 2018: GLOBOCAN estimates of inci-dence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018,68(6),394-424","journal-title":"CA Cancer J Clin"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.canlet.2015.07.044","volume":"380","author":"Sun Y.","year":"2016","unstructured":"Sun Y.; Tumor microenvironment and cancer therapy resistance. Cancer Lett 2016,380(1),205-215","journal-title":"Cancer Lett"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","volume":"18","author":"Jing X.","year":"2019","unstructured":"Jing X.; Yang F.; Shao C.; Wei K.; Xie M.; Shen H.; Shu Y.; Role of hypoxia in cancer therapy by regulating the tumor microenviron-ment. Mol Cancer 2019,18(1),157","journal-title":"Mol Cancer"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc704","volume":"2","author":"Harris A.L.","year":"2002","unstructured":"Harris A.L.; Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2002,2(1),38-47","journal-title":"Nat Rev Cancer"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.suronc.2011.09.001","volume":"21","author":"Weber C.E.","year":"2012","unstructured":"Weber C.E.; Kuo P.C.; The tumor microenvironment. Surg Oncol 2012,21(3),172-177","journal-title":"Surg Oncol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00109-007-0281-3","volume":"85","author":"Brahimi-Horn M.C.","year":"2007","unstructured":"Brahimi-Horn M.C.; Chiche J.; Pouyss\u00e9gur J.; Hypoxia and cancer. J Mol Med 2007,85(12),1301-1307","journal-title":"J Mol Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/cells6040045","volume":"6","author":"Monteiro A.R.","year":"2017","unstructured":"Monteiro A.R.; Hill R.; Pilkington G.J.; Madureira P.A.; The role of hypoxia in glioblastoma invasion. Cells 2017,6(4),45","journal-title":"Cells"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1007\/s00018-019-03444-3","volume":"77","author":"Tan Z.","year":"2020","unstructured":"Tan Z.; Xu J.; Zhang B.; Shi S.; Yu X.; Liang C.; Hypoxia: A barricade to conquer the pancreatic cancer. Cell Mol Life Sci 2020,77(16),3077-3083","journal-title":"Cell Mol Life Sci"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature04871","volume":"441","author":"Pouyss\u00e9gur J.","year":"2006","unstructured":"Pouyss\u00e9gur J.; Dayan F.; Mazure N.M.; Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006,441(7092),437-443","journal-title":"Nature"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"46691","DOI":"10.18632\/oncotarget.17358","volume":"8","author":"Chen C.","year":"2017","unstructured":"Chen C.; Lou T.; Hypoxia inducible factors in hepatocellular carcinoma. Oncotarget 2017,8(28),46691-46703","journal-title":"Oncotarget"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1269\/jrr.11117","volume":"52","author":"Shioya M.","year":"2011","unstructured":"Shioya M.; Takahashi T.; Ishikawa H.; Sakurai H.; Ebara T.; Suzuki Y.; Saitoh J.; Ohno T.; Asao T.; Kuwano H.; Nakano T.; Ex-pression of hypoxia-inducible factor 1\u03b1 predicts clinical outcome after preoperative hyperthermo-chemoradiotherapy for locally ad-vanced rectal cancer. J Radiat Res 2011,52(6),821-827","journal-title":"J Radiat Res"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1021\/jm401375q","volume":"57","author":"Ilardi E.A.","year":"2014","unstructured":"Ilardi E.A.; Vitaku E.; Njardarson J.T.; Data-mining for sulfur and fluorine: An evaluation of pharmaceuticals to reveal opportunities for drug design and discovery. J Med Chem 2014,57(7),2832-2842","journal-title":"J Med Chem"},{"key":"ref=14","author":"Brase S.","year":"2016","unstructured":"Brase S.;  Privileged Scaffolds in Medicinal Chemistry 2016","journal-title":"Privileged Scaffolds in Medicinal Chemistry"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.24820\/ark.5550190.p010.573","volume":"5","author":"Nural Y.","year":"2018","unstructured":"Nural Y.; Gemili M.; Yabalak E.; Coen L.D.; Ulger M.; Green synthesis of highly functionalized octahydropyrrolo[3,4-c]pyrrole deriv-atives using subcritical water, and their anti(myco)bacterial and antifungal activity. ARKIVOC 2018,5(5),51-64","journal-title":"ARKIVOC"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s00706-018-2250-7","volume":"149","author":"Nural Y.","year":"2018","unstructured":"Nural Y.; Synthesis, antimycobacterial activity, and acid dissociation constants of polyfunctionalized 3-[2-(pyrrolidin-1-yl)thiazole-5-carbonyl]-2H-chromen-2-one derivatives. Monatsh Chem 2018,149(10),1905-1918","journal-title":"Monatsh Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1517\/13543776.2014.999764","volume":"25","author":"Kamal A.","year":"2015","unstructured":"Kamal A.; Syed M.A.; Mohammed S.M.; Therapeutic potential of benzothiazoles: A patent review (2010-2014). Expert Opin Ther Pat 2015,25,335-349","journal-title":"Expert Opin Ther Pat"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1055\/s-0035-1560722","volume":"27","author":"Blunt C.E.","year":"2016","unstructured":"Blunt C.E.; Nawrat C.C.; LeBozec L.; Liutkus M.; Liu Y.; Lewis W.; Moody C.J.; Oxidative routes to the heterocyclic cores of benzo-thiazole natural products. Synlett 2016,27(1),37-40","journal-title":"Synlett"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/ejoc.201901502","volume":"2020","author":"Liu X.","year":"2020","unstructured":"Liu X.; Dong Z.B.; A review on domino condensation\/cyclization reactions for the synthesis of 2\u2010substituted 1,3\u2010benzothiazole deriva-tives. Eur J Org Chem 2020,2020(4),408-419","journal-title":"Eur J Org Chem"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.ejmech.2014.10.058","volume":"97","author":"Rouf A.","year":"2015","unstructured":"Rouf A.; Tanyeli C.; Bioactive thiazole and benzothiazole derivatives. Eur J Med Chem 2015,97,911-927","journal-title":"Eur J Med Chem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1071\/CH09126","volume":"62","author":"Le Bozec L.","year":"2009","unstructured":"Le Bozec L.; Moody C.J.; Naturally occurring nitrogen-sulfur compounds. The benzothiazole alkaloids. Aust J Chem 2009,62(7),639-647","journal-title":"Aust J Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"112618","DOI":"10.1016\/j.ejmech.2020.112618","volume":"203","author":"Song J.","year":"2020","unstructured":"Song J.; Gao Q.L.; Wu B.W.; Zhu T.; Cui X.X.; Jin C.J.; Wang S.Y.; Wang S.H.; Fu D.J.; Liu H.M.; Zhang S.Y.; Zhang Y.B.; Li Y.C.; Discovery of tertiary amide derivatives incorporating benzothiazole moiety as anti-gastric cancer agents in vitro via inhibiting tubulin polymerization and activating the Hippo signaling pathway. Eur J Med Chem 2020,203,112618","journal-title":"Eur J Med Chem"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.bioorg.2017.12.037","volume":"77","author":"Bhutani R.","year":"2018","unstructured":"Bhutani R.; Pathak D.P.; Kapoor G.; Husain A.; Kant R.; Iqbal M.A.; Synthesis, molecular modelling studies and ADME prediction of benzothiazole clubbed oxadiazole-Mannich bases, and evaluation of their anti-diabetic activity through in vivo model. Bioorg Chem 2018,77,6-15","journal-title":"Bioorg Chem"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"103960","DOI":"10.1016\/j.bioorg.2020.103960","volume":"101","author":"Djuidje E.N.","year":"2020","unstructured":"Djuidje E.N.; Sciabica S.; Buzzi R.; Dissette V.; Balzarini J.; Liekens S.; Serra E.; Andreotti E.; Manfredini S.; Vertuani S.; Baldis-serotto A.; Design, synthesis and evaluation of benzothiazole derivatives as multifunctional agents. Bioorg Chem 2020,101,103960","journal-title":"Bioorg Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/14756366.2019.1698036","volume":"35","author":"Irfan A.","year":"2020","unstructured":"Irfan A.; Batool F.; Zahra Naqvi S.A.; Islam A.; Osman S.M.; Nocentini A.; Alissa S.A.; Supuran C.T.; Benzothiazole derivatives as anticancer agents. J Enzyme Inhib Med Chem 2020,35(1),265-279","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2174\/1570193X16666190204111502","volume":"17","author":"Bhat M.","year":"2020","unstructured":"Bhat M.; Belagali S.L.; Structural activity relationship and importance of benzothiazole derivatives in medicinal chemistry: A comprehen-sive review. Mini Rev Org Chem 2020,17(3),323-350","journal-title":"Mini Rev Org Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2174\/1389557519666190617153213","volume":"20","author":"Pathak N.","year":"2020","unstructured":"Pathak N.; Rathi E.; Kumar N.; Kini S.G.; Rao C.M.; A review on anticancer potentials of benzothiazole derivatives. Mini Rev Med Chem 2020,20(1),12-23","journal-title":"Mini Rev Med Chem"},{"key":"ref=28","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.201800170","volume":"352","author":"Tariq S.","year":"2019","unstructured":"Tariq S.; Kamboj P.; Amir M.; Therapeutic advancement of benzothiazole derivatives in the last decennial period. Arch Pharm (Weinheim) 2019,352(1)","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"729","DOI":"10.2174\/1570178614666170707160654","volume":"14","author":"Agarwal S.","year":"2017","unstructured":"Agarwal S.; Gandhi D.; Kalal P.; Benzothiazole: A versatile and multi targeted pharmacophore in the field of medicinal chemistry. Lett Org Chem 2017,14(10),729-742","journal-title":"Lett Org Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ejmech.2014.10.059","volume":"89","author":"Keri R.S.","year":"2015","unstructured":"Keri R.S.; Patil M.R.; Patil S.A.; Budagumpi S.; A comprehensive review in current developments of benzothiazole-based molecules in medicinal chemistry. Eur J Med Chem 2015,89,207-251","journal-title":"Eur J Med Chem"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3109\/14756366.2012.720572","volume":"28","author":"Sharma P.C.","year":"2013","unstructured":"Sharma P.C.; Sinhmar A.; Sharma A.; Rajak H.; Pathak D.P.; Medicinal significance of benzothiazole scaffold: An insight view. J Enzyme Inhib Med Chem 2013,28(2),240-266","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2174\/138955706777435706","volume":"6","author":"Dubey R.","year":"2006","unstructured":"Dubey R.; Shrivastava P.K.; Basniwal P.K.; Bhattacharya S.; Moorthy N.S.; 2-(4-aminophenyl) benzothiazole: A potent and selective pharmacophore with novel mechanistic action towards various tumour cell lines. Mini Rev Med Chem 2006,6(6),633-637","journal-title":"Mini Rev Med Chem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/S0002-9440(10)63747-9","volume":"164","author":"Michiels C.","year":"2004","unstructured":"Michiels C.; Physiological and pathological responses to hypoxia. Am J Pathol 2004,164(6),1875-1882","journal-title":"Am J Pathol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S0959-437X(98)80016-6","volume":"8","author":"Semenza G.L.","year":"1998","unstructured":"Semenza G.L.; Hypoxia-inducible factor 1: Master regulator of O2 homeostasis. Curr Opin Genet Dev 1998,8(5),588-594","journal-title":"Curr Opin Genet Dev"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1056\/NEJM198612253152606","volume":"315","author":"Dvorak H.F.","year":"1986","unstructured":"Dvorak H.F.; Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986,315(26),1650-1659","journal-title":"N Engl J Med"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-3-030-51652-9_17","volume":"1280","author":"Elzakra N.","year":"2021","unstructured":"Elzakra N.; Kim Y.; HIF-1\u03b1 Metabolic pathways in human cancer. Adv Exp Med Biol 2021,1280,243-260","journal-title":"Adv Exp Med Biol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41389-017-0011-9","volume":"7","author":"Petrova V.","year":"2018","unstructured":"Petrova V.; Annicchiarico-Petruzzelli M.; Melino G.; Amelio I.; The hypoxic tumour microenvironment. Oncogenesis 2018,7(1),10","journal-title":"Oncogenesis"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/HP.S93413","volume":"3","author":"Muz B.","year":"2015","unstructured":"Muz B.; de la Puente P.; Azab F.; Azab A.K.; The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl) 2015,3,83-92","journal-title":"Hypoxia (Auckl)"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/med.21477","volume":"38","author":"Bhattarai D.","year":"2018","unstructured":"Bhattarai D.; Xu X.; Lee K.; Hypoxia-Inducible Factor-1 (HIF-1) inhibitors from the last decade (2007 to 2016): A \u201cstructure-activity relationship\u201d perspective. Med Res Rev 2018,38(4),1404-1442","journal-title":"Med Res Rev"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1152\/jappl.2000.88.4.1474","volume":"88","author":"Semenza G.L.","year":"2000","unstructured":"Semenza G.L.; HIF-1: Mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000,88(4),1474-1480","journal-title":"J Appl Physiol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.yexcr.2017.03.008","volume":"356","author":"Pugh C.W.","year":"2017","unstructured":"Pugh C.W.; Ratcliffe P.J.; New horizons in hypoxia signaling pathways. Exp Cell Res 2017,356(2),116-121","journal-title":"Exp Cell Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1073\/pnas.90.9.4304","volume":"90","author":"Wang G.L.","year":"1993","unstructured":"Wang G.L.; Semenza G.L.; General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci 1993,90(9),4304-4308","journal-title":"Proc Natl Acad Sci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/00062752-199603020-00009","volume":"3","author":"Wang G.L.","year":"1996","unstructured":"Wang G.L.; Semenza G.L.; Molecular basis of hypoxia-induced erythropoietin expression. Curr Opin Hematol 1996,3(2),156-162","journal-title":"Curr Opin Hematol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"C260","DOI":"10.1152\/ajpcell.00315.2015","volume":"310","author":"Duan C.","year":"2016","unstructured":"Duan C.; Hypoxia-inducible factor 3 biology: Complexities and emerging themes. Am J Physiol Cell Physiol 2016,310(4),C260-C269","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","volume":"92","author":"Wang G.L.","year":"1995","unstructured":"Wang G.L.; Jiang B.H.; Rue E.A.; Semenza G.L.; Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci 1995,92(12),5510-5514","journal-title":"Proc Natl Acad Sci"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/S1471-4914(02)02317-1","volume":"8","author":"Semenza G.L.","year":"2002","unstructured":"Semenza G.L.; HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol Med 2002,8(4)(Suppl.),S62-S67","journal-title":"Trends Mol Med"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1177\/1535370220934038","volume":"245","author":"Roy S.","year":"2020","unstructured":"Roy S.; Kumaravel S.; Sharma A.; Duran C.L.; Bayless K.J.; Chakraborty S.; Hypoxic tumor microenvironment: Implications for can-cer therapy. Exp Biol Med 2020,245(13),1073-1086","journal-title":"Exp Biol Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"5907","DOI":"10.1038\/sj.onc.1206703","volume":"22","author":"Denko N.C.","year":"2003","unstructured":"Denko N.C.; Fontana L.A.; Hudson K.M.; Sutphin P.D.; Raychaudhuri S.; Altman R.; Giaccia A.J.; Investigating hypoxic tumor phys-iology through gene expression patterns. Oncogene 2003,22(37),5907-5914","journal-title":"Oncogene"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"e46401","DOI":"10.15252\/embr.201846401","volume":"20","author":"Smythies J.A.","year":"2019","unstructured":"Smythies J.A.; Sun M.; Masson N.; Salama R.; Simpson P.D.; Murray E.; Neumann V.; Cockman M.E.; Choudhry H.; Ratcliffe P.J.; Mole D.R.; Inherent DNA-binding specificities of the HIF-1\u03b1 and HIF-2\u03b1 transcription factors in chromatin. EMBO Rep 2019,20(1),e46401","journal-title":"EMBO Rep"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1096\/fj.02-0445fje","volume":"17","author":"Wiesener M.S.","year":"2003","unstructured":"Wiesener M.S.; J\u00fcrgensen J.S.; Rosenberger C.; Scholze C.K.; H\u00f6rstrup J.H.; Warnecke C.; Mandriota S.; Bechmann I.; Frei U.A.; Pugh C.W.; Ratcliffe P.J.; Bachmann S.; Maxwell P.H.; Eckardt K.U.; Widespread hypoxia-inducible expression of HIF-2alpha in dis-tinct cell populations of different organs. FASEB J 2003,17(2),271-273","journal-title":"FASEB J"},{"key":"ref=51","first-page":"471","volume":"8","author":"Onita T.","year":"2002","unstructured":"Onita T.; Ji P.G.; Xuan J.W.; Sakai H.; Kanetake H.; Maxwell P.H.; Fong G-H.; Gabril M.Y.; Moussa M.; Chin J.L.; Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1\/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. Clin Cancer Res 2002,8(2),471-480","journal-title":"Clin Cancer Res"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc3183","volume":"12","author":"Keith B.","year":"2011","unstructured":"Keith B.; Johnson R.S.; Simon M.C.; HIF1\u03b1 and HIF2\u03b1: Sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2011,12(1),9-22","journal-title":"Nat Rev Cancer"},{"key":"ref=53","first-page":"1326","volume":"62","author":"Leek R.D.","year":"2002","unstructured":"Leek R.D.; Talks K.L.; Pezzella F.; Turley H.; Campo L.; Brown N.S.; Bicknell R.; Taylor M.; Gatter K.C.; Harris A.L.; Relation of hypoxia-inducible factor-2 \u03b1 (HIF-2 \u03b1) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. Cancer Res 2002,62(5),1326-1329","journal-title":"Cancer Res"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1182\/blood.V92.7.2260","volume":"92","author":"Wiesener M.S.","year":"1998","unstructured":"Wiesener M.S.; Turley H.; Allen W.E.; Willam C.; Eckardt K.U.; Talks K.L.; Wood S.M.; Gatter K.C.; Harris A.L.; Pugh C.W.; Ratcliffe P.J.; Maxwell P.H.; Induction of endothelial PAS domain protein-1 by hypoxia: Characterization and comparison with hypoxia-inducible factor-1alpha. Blood 1998,92(7),2260-2268","journal-title":"Blood"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S0092-8674(00)81731-6","volume":"94","author":"Fukumura D.","year":"1998","unstructured":"Fukumura D.; Xavier R.; Sugiura T.; Chen Y.; Park E.C.; Lu N.; Selig M.; Nielsen G.; Taksir T.; Jain R.K.; Seed B.; Tumor induc-tion of VEGF promoter activity in stromal cells. Cell 1998,94(6),715-725","journal-title":"Cell"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0002-9440(10)65541-1","volume":"153","author":"Flamme I.","year":"1998","unstructured":"Flamme I.; Krieg M.; Plate K.H.; Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF\/HIF-2alpha. Am J Pathol 1998,153(1),25-29","journal-title":"Am J Pathol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1134\/S0026893317020194","volume":"51","author":"Spirina L.V.","year":"2017","unstructured":"Spirina L.V.; Usynin Y.A.; Yurmazov Z.A.; Slonimskaya E.M.; Kolegova E.S.; Kondakova I.V.; Transcription factors NF-kB, HIF-1, HIF-2, growth factor VEGF, VEGFR2 and carboanhydrase IX mRNA and protein level in the development of kidney cancer metastasis Mol Biol 2017,51(2),372-377","journal-title":"Mol Biol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/1097-0142(20010415)91:8<1429::AID-CNCR1149>3.0.CO;2-V","volume":"91","author":"Xia G.","year":"2001","unstructured":"Xia G.; Kageyama Y.; Hayashi T.; Kawakami S.; Yoshida M.; Kihara K.; Regulation of vascular endothelial growth factor transcription by endothelial PAS domain protein 1 (EPAS1) and possible involvement of EPAS1 in the angiogenesis of renal cell carcinoma. Cancer 2001,91(8),1429-1436","journal-title":"Cancer"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/S0002-9440(10)64400-8","volume":"161","author":"Favier J.","year":"2002","unstructured":"Favier J.; Plouin P.F.; Corvol P.; Gasc J.M.; Angiogenesis and vascular architecture in pheochromocytomas: Distinctive traits in malig-nant tumors. Am J Pathol 2002,161(4),1235-1246","journal-title":"Am J Pathol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ccr.2006.08.026","volume":"10","author":"Holmquist-Mengelbier L.","year":"2006","unstructured":"Holmquist-Mengelbier L.; Fredlund E.; L\u00f6fstedt T.; Noguera R.; Navarro S.; Nilsson H.; Pietras A.; Vallon-Christersson J.; Borg A.; Gradin K.; Poellinger L.; P\u00e5hlman S.; Recruitment of HIF-1\u03b1 and HIF-2\u03b1 to common target genes is differentially regulated in neuroblas-toma: HIF-2\u03b1 promotes an aggressive phenotype. Cancer Cell 2006,10(5),413-423","journal-title":"Cancer Cell"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"32405","DOI":"10.1074\/jbc.C200328200","volume":"277","author":"Makino Y.","year":"2002","unstructured":"Makino Y.; Kanopka A.; Wilson W.J.; Tanaka H.; Poellinger L.; Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J Biol Chem 2002,277(36),32405-32408","journal-title":"J Biol Chem"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1006\/bbrc.2001.5659","volume":"287","author":"Hara S.","year":"2001","unstructured":"Hara S.; Hamada J.; Kobayashi C.; Kondo Y.; Imura N.; Expression and characterization of Hypoxia-Inducible Factor (HIF)-3alpha in human kidney: Suppression of HIF-mediated gene expression by HIF-3alpha. Biochem Biophys Res Commun 2001,287(4),808-813","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1007\/s00018-011-0679-5","volume":"68","author":"Heikkil\u00e4 M.","year":"2011","unstructured":"Heikkil\u00e4 M.; Pasanen A.; Kivirikko K.I.; Myllyharju J.; Roles of the human Hypoxia-Inducible Factor (HIF)-3\u03b1 variants in the hypoxia response. Cell Mol Life Sci 2011,68(23),3885-3901","journal-title":"Cell Mol Life Sci"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3389\/fonc.2020.00562","volume":"10","author":"S\u00f8rensen B.S.","year":"2020","unstructured":"S\u00f8rensen B.S.; Horsman M.R.; Tumor hypoxia: Impact on radiation therapy and molecular pathways. Front Oncol 2020,10,562","journal-title":"Front Oncol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1096\/fj.02-0993fje","volume":"17","author":"Nikitenko L.L.","year":"2003","unstructured":"Nikitenko L.L.; Smith D.M.; Bicknell R.; Rees M.C.P.; Transcriptional regulation of the CRLR gene in human microvascular endothelial cells by hypoxia. FASEB J 2003,17(11),1499-1501","journal-title":"FASEB J"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1161\/01.RES.0000102937.50486.1B","volume":"93","author":"Kelly B.D.","year":"2003","unstructured":"Kelly B.D.; Hackett S.F.; Hirota K.; Oshima Y.; Cai Z.; Berg-Dixon S.; Rowan A.; Yan Z.; Campochiaro P.A.; Semenza G.L.; Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitu-tively active form of hypoxia-inducible factor 1. Circ Res 2003,93(11),1074-1081","journal-title":"Circ Res"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nm0603-677","volume":"9","author":"Pugh C.W.","year":"2003","unstructured":"Pugh C.W.; Ratcliffe P.J.; Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 2003,9(6),677-684","journal-title":"Nat Med"},{"key":"ref=68","first-page":"4729","volume":"18","author":"Riva C.","year":"1998","unstructured":"Riva C.; Chauvin C.; Pison C.; Leverve X.; Cellular physiology and molecular events in hypoxia-induced apoptosis. Anticancer Res 1998,18(6B),4729-4736","journal-title":"Anticancer Res"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"12207","DOI":"10.1074\/jbc.M212360200","volume":"278","author":"Hammond E.M.","year":"2003","unstructured":"Hammond E.M.; Dorie M.J.; Giaccia A.J.; ATR\/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J Biol Chem 2003,278(14),12207-12213","journal-title":"J Biol Chem"},{"key":"ref=70","first-page":"6548","volume":"61","author":"Akakura N.","year":"2001","unstructured":"Akakura N.; Kobayashi M.; Horiuchi I.; Suzuki A.; Wang J.; Chen J.; Niizeki H.; Kawamura Ki; Hosokawa, M.; Asaka, M. Constitu-tive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 2001,61(17),6548-6554","journal-title":"Cancer Res"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/28867","volume":"394","author":"Carmeliet P.","year":"1998","unstructured":"Carmeliet P.; Dor Y.; Herbert J-M.; Fukumura D.; Brusselmans K.; Dewerchin M.; Neeman M.; Bono F.; Abramovitch R.; Maxwell P.; Koch C.J.; Ratcliffe P.; Moons L.; Jain R.K.; Collen D.; Keshert E.; Role of HIF-1alpha in hypoxia-mediated apoptosis, cell prolif-eration and tumour angiogenesis. Nature 1998,394(6692),485-490","journal-title":"Nature"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"10004","DOI":"10.1074\/jbc.M805997200","volume":"284","author":"Chen N.","year":"2009","unstructured":"Chen N.; Chen X.; Huang R.; Zeng H.; Gong J.; Meng W.; Lu Y.; Zhao F.; Wang L.; Zhou Q.; BCL-xL is a target gene regulated by hypoxia-inducible factor-1\u03b1. J Biol Chem 2009,284(15),10004-10012","journal-title":"J Biol Chem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1128\/MCB.24.7.2875-2889.2004","volume":"24","author":"Erler J.T.","year":"2004","unstructured":"Erler J.T.; Cawthorne C.J.; Williams K.J.; Koritzinsky M.; Wouters B.G.; Wilson C.; Miller C.; Demonacos C.; Stratford I.J.; Dive C.; Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mecha-nisms and contributes to drug resistance. Mol Cell Biol 2004,24(7),2875-2889","journal-title":"Mol Cell Biol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.neuroscience.2014.08.019","volume":"278","author":"Trollmann R.","year":"2014","unstructured":"Trollmann R.; Richter M.; Jung S.; Walkinshaw G.; Brackmann F.; Pharmacologic stabilization of hypoxia-inducible transcription fac-tors protects developing mouse brain from hypoxia-induced apoptotic cell death. Neuroscience 2014,278,327-342","journal-title":"Neuroscience"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13045-020-01030-w","volume":"14","author":"Tao J.","year":"2021","unstructured":"Tao J.; Yang G.; Zhou W.; Qiu J.; Chen G.; Luo W.; Zhao F.; You L.; Zheng L.; Zhang T.; Zhao Y.; Targeting hypoxic tumor mi-croenvironment in pancreatic cancer. J Hematol Oncol 2021,14(1),14","journal-title":"J Hematol Oncol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"445","DOI":"10.18388\/abp.2004_3583","volume":"51","author":"Okegawa T.","year":"2004","unstructured":"Okegawa T.; Pong R.C.; Li Y.; Hsieh J.T.; The role of cell adhesion molecule in cancer progression and its application in cancer therapy. Acta Biochim Pol 2004,51(2),445-457","journal-title":"Acta Biochim Pol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1091\/mbc.e04-12-1082","volume":"16","author":"Cowden Dahl K.D.","year":"2005","unstructured":"Cowden Dahl K.D.; Robertson S.E.; Weaver V.M.; Simon M.C.; Hypoxia-inducible factor regulates alphavbeta3 integrin cell surface expression. Mol Biol Cell 2005,16(4),1901-1912","journal-title":"Mol Biol Cell"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bbrc.2010.01.060","volume":"393","author":"Ryu M.H.","year":"2010","unstructured":"Ryu M.H.; Park H.M.; Chung J.; Lee C.H.; Park H.R.; Hypoxia-inducible factor-1alpha mediates oral squamous cell carcinoma invasion via upregulation of alpha5 integrin and fibronectin. Biochem Biophys Res Commun 2010,393(1),11-15","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/jcp.22358","volume":"226","author":"Lee S.H.","year":"2011","unstructured":"Lee S.H.; Lee Y.J.; Han H.J.; Role of hypoxia-induced fibronectin-integrin \u03b21 expression in embryonic stem cell proliferation and migra-tion: Involvement of PI3K\/Akt and FAK. J Cell Physiol 2011,226(2),484-493","journal-title":"J Cell Physiol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3109\/02713683.2010.534573","volume":"36","author":"Barak V.","year":"2011","unstructured":"Barak V.; Pe\u2019er J.; Kalickman I.; Frenkel S.; VEGF as a biomarker for metastatic uveal melanoma in humans. Curr Eye Res 2011,36(4),386-390","journal-title":"Curr Eye Res"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"39273","DOI":"10.1074\/jbc.M509446200","volume":"280","author":"Lester R.D.","year":"2005","unstructured":"Lester R.D.; Jo M.; Campana W.M.; Gonias S.L.; Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK\/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J Biol Chem 2005,280(47),39273-39277","journal-title":"J Biol Chem"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1093\/carcin\/bgn216","volume":"29","author":"Cannito S.","year":"2008","unstructured":"Cannito S.; Novo E.; Compagnone A.; Valfr\u00e8 di Bonzo L.; Busletta C.; Zamara E.; Paternostro C.; Povero D.; Bandino A.; Bozzo F.; Cravanzola C.; Bravoco V.; Colombatto S.; Parola M.; Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transi-tion in cancer cells. Carcinogenesis 2008,29(12),2267-2278","journal-title":"Carcinogenesis"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"e62310","DOI":"10.1371\/journal.pone.0062310","volume":"8","author":"Matsuoka J.","year":"2013","unstructured":"Matsuoka J.; Yashiro M.; Doi Y.; Fuyuhiro Y.; Kato Y.; Shinto O.; Noda S.; Kashiwagi S.; Aomatsu N.; Hirakawa T.; Hasegawa T.; Shimizu K.; Shimizu T.; Miwa A.; Yamada N.; Sawada T.; Hirakawa K.; Hypoxia stimulates the EMT of gastric cancer cells through autocrine TGF\u03b2 signaling. PLoS One 2013,8(5),e62310","journal-title":"PLoS One"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"111609","DOI":"10.1016\/j.ejmech.2019.111609","volume":"182","author":"Reddy V.G.","year":"2019","unstructured":"Reddy V.G.; Reddy T.S.; Jadala C.; Reddy M.S.; Sultana F.; Akunuri R.; Bhargava S.K.; Wlodkowic D.; Srihari P.; Kamal A.; Pyra-zolo-benzothiazole hybrids: Synthesis, anticancer properties and evaluation of antiangiogenic activity using in vitro VEGFR-2 kinase and in vivo transgenic zebrafish model. Eur J Med Chem 2019,182,111609","journal-title":"Eur J Med Chem"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/14756366.2019.1591391","volume":"34","author":"Liu D.C.","year":"2019","unstructured":"Liu D.C.; Gao M.J.; Huo Q.; Ma T.; Wang Y.; Wu C.Z.; Design, synthesis, and apoptosis-promoting effect evaluation of novel pyra-zole with benzo[d]thiazole derivatives containing aminoguanidine units. J Enzyme Inhib Med Chem 2019,34(1),829-837","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.bmc.2019.01.011","volume":"27","author":"Nagaraju B.","year":"2019","unstructured":"Nagaraju B.; Kovvuri J.; Kumar C.G.; Routhu S.R.; Shareef M.A.; Kadagathur M.; Adiyala P.R.; Alavala S.; Nagesh N.; Kamal A.; Synthesis and biological evaluation of pyrazole linked benzothiazole-&#x3B2;-naphthol derivatives as topoisomerase I inhibitors with DNA binding ability. Bioorg Med Chem 2019,27(5),708-720","journal-title":"Bioorg Med Chem"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nature03097","volume":"432","author":"Kastan M.B.","year":"2004","unstructured":"Kastan M.B.; Bartek J.; Cell-cycle checkpoints and cancer. Nature 2004,432(7015),316-323","journal-title":"Nature"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1007\/s11164-016-2851-x","volume":"43","author":"Belal A.","year":"2017","unstructured":"Belal A.; Abdelgawad, M.A. New benzothiazole\/benzoxazole-pyrazole hybrids with potential as COX inhibitors: Design, synthesis and anticancer activity evaluation. Res Chem Intermed 2017,43(7),3859-3872","journal-title":"Res Chem Intermed"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/00001813-200202000-00003","volume":"13","author":"Xu X.C.","year":"2002","unstructured":"Xu X.C.; COX-2 inhibitors in cancer treatment and prevention, a recent development. Anticancer Drugs 2002,13(2),127-137","journal-title":"Anticancer Drugs"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.bioorg.2017.07.007","volume":"74","author":"Abdelgawad M.A.","year":"2017","unstructured":"Abdelgawad M.A.; Bakr R.B.; Omar H.A.; Design, synthesis and biological evaluation of some novel benzothiazole\/benzoxazole and\/or benzimidazole derivatives incorporating a pyrazole scaffold as antiproliferative agents. Bioorg Chem 2017,74,82-90","journal-title":"Bioorg Chem"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"6926","DOI":"10.1080\/07391102.2020.1803966","volume":"39","author":"Algul O.","year":"2021","unstructured":"Algul O.; Ersan R.H.; Alagoz M.A.; Duran N.; Burmaoglu S.; An efficient synthesis of novel di-heterocyclic benzazole derivatives and evaluation of their antiproliferative activities. J Biomol Struct Dyn 2021,39(18),6926-6938","journal-title":"J Biomol Struct Dyn"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1515\/tjb-2017-0015","volume":"42","author":"Yurtta\u015f L.","year":"2017","unstructured":"Yurtta\u015f L.; \u00c7avu\u015fo\u011flu B.K.; Sever A.; \u00c7ift\u00e7i G.A.; A preliminary investigation of anticancer activity of novel benzothiazole derivatives against A549 lung carcinoma cell line. Turk Biyokim Derg 2017,42(5),535-544","journal-title":"Turk Biyokim Derg"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1016\/j.bmcl.2017.07.051","volume":"27","author":"Baig M.F.","year":"2017","unstructured":"Baig M.F.; Shaik S.P.; Nayak V.L.; Alarifi A.; Kamal A.; Iodine-catalyzed Csp3-H functionalization of methylhetarenes: One-pot synthe-sis and cytotoxic evaluation of heteroarenyl-benzimidazoles and benzothiazole. Bioorg Med Chem Lett 2017,27(17),4039-4043","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"104133","DOI":"10.1016\/j.bioorg.2020.104133","volume":"103","author":"Rezki N.","year":"2020","unstructured":"Rezki N.; Almehmadi M.A.; Ihmaid S.; Shehata A.M.; Omar A.M.; Ahmed H.E.A.; Aouad M.R.; Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses. Bioorg Chem 2020,103,104133","journal-title":"Bioorg Chem"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.pharmthera.2004.01.002","volume":"102","author":"Grandis J.R.","year":"2004","unstructured":"Grandis J.R.; Sok J.C.; Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004,102(1),37-46","journal-title":"Pharmacol Ther"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/14728222.2011.648617","volume":"16","author":"Seshacharyulu P.","year":"2012","unstructured":"Seshacharyulu P.; Ponnusamy M.P.; Haridas D.; Jain M.; Ganti A.K.; Batra S.K.; Targeting the EGFR signaling pathway in cancer ther-apy. Expert Opin Ther Targets 2012,16(1),15-31","journal-title":"Expert Opin Ther Targets"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1134\/S1070363219050220","volume":"89","author":"Pragathi Y.J.","year":"2019","unstructured":"Pragathi Y.J.; Sreenivasulu R.; Veronica D.; Madhavi S.; Raju R.R.; Design, synthesis, and biological evaluation of novel 2-(4-arylsubstituted-1H,2,3-triazol-1-yl)-N-{4-[2-(thiazol-2-yl)benzo[d]thiazol-6-yl]phenyl}acetamide derivatives as potent anticancer agents. Russ J Gen Chem 2019,89(5),1009-1014","journal-title":"Russ J Gen Chem"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.3390\/molecules23112788","volume":"23","author":"Aouad M.R.","year":"2018","unstructured":"Aouad M.R.; Soliman M.A.; Alharbi M.O.; Bardaweel S.K.; Sahu P.K.; Ali A.A.; Messali M.; Rezki N.; Al-Soud Y.A.; Design, syn-thesis and anticancer screening of novel benzothiazole-piperazine-1, 2, 3-triazole hybrids. Molecules 2018,23(11),2788","journal-title":"Molecules"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"4527","DOI":"10.1016\/j.bmcl.2016.06.044","volume":"26","author":"Ashraf M.","year":"2016","unstructured":"Ashraf M.; Shaik T.B.; Malik M.S.; Syed R.; Mallipeddi P.L.; Vardhan M.V.P.S.V.; Kamal A.; Design and synthesis of cis-restricted benzimidazole and benzothiazole mimics of combretastatin A-4 as antimitotic agents with apoptosis inducing ability. Bioorg Med Chem Lett 2016,26(18),4527-4535","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"7150","DOI":"10.1039\/C8NJ06517A","volume":"43","author":"Sultana F.","year":"2019","unstructured":"Sultana F.; Saifi M.A.; Syed R.; Mani G.S.; Shaik S.P.; Osas E.G.S.; Godugu C.; Shahjahan S.; Kamal A.; Synthesis of 2-anilinopyridyl linked benzothiazolehydrazones as apoptosis inducing cytotoxic agents. New J Chem 2019,43(18),7150-7161","journal-title":"New J Chem"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1039\/C8MD00624E","volume":"10","author":"Ma J.","year":"2019","unstructured":"Ma J.; Ni X.; Gao Y.; Huang K.; Liu J.; Wang Y.; Chen R.; Wang C.; Identification and biological evaluation of novel benzothiazole derivatives bearing a pyridine-semicarbazone moiety as apoptosis inducers via activation of procaspase-3 to caspase-3. MedChemComm 2019,10(3),465-477","journal-title":"MedChemComm"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ejmech.2019.06.055","volume":"179","author":"Diao P.C.","year":"2019","unstructured":"Diao P.C.; Lin W.Y.; Jian X.E.; Li Y.H.; You W.W.; Zhao P.L.; Discovery of novel pyrimidine-based benzothiazole derivatives as potent cyclin-dependent kinase 2 inhibitors with anticancer activity. Eur J Med Chem 2019,179,196-207","journal-title":"Eur J Med Chem"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.gde.2006.12.008","volume":"17","author":"Malumbres M.","year":"2007","unstructured":"Malumbres M.; Barbacid M.; Cell cycle kinases in cancer. Curr Opin Genet Dev 2007,17(1),60-65","journal-title":"Curr Opin Genet Dev"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"E1019","DOI":"10.1073\/pnas.1111317109","volume":"109","author":"Horiuchi D.","year":"2012","unstructured":"Horiuchi D.; Huskey N.E.; Kusdra L.; Wohlbold L.; Merrick K.A.; Zhang C.; Creasman K.J.; Shokat K.M.; Fisher R.P.; Goga A.; Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogen-ic pathways. Proc Natl Acad Sci 2012,109(17),E1019-E1027","journal-title":"Proc Natl Acad Sci"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.6023\/cjoc201902036","volume":"40","author":"Luye Z.","year":"2020","unstructured":"Luye Z.; Yang Z.; Zhengjie W.; Tao W.; Limin L.; Xiujuan L.; Erdong L.; Panpan S.; Jiaxin Z.; Yu K.; Lihong S.; Hongmin L.; Qiurong Z.; Synthesis and antitumor activity of novel 4-aminoquinazoline derivatives containing benzothiazole. Youji Huaxue 2020,40(7),1967-1974","journal-title":"Youji Huaxue"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"104053","DOI":"10.1016\/j.bioorg.2020.104053","volume":"102","author":"Husseiny E.M.","year":"2020","unstructured":"Husseiny E.M.; Synthesis, cytotoxicity of some pyrazoles and pyrazolo[1,5-a]pyrimidines bearing benzothiazole moiety and investiga-tion of their mechanism of action. Bioorg Chem 2020,102,104053","journal-title":"Bioorg Chem"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1016\/j.bmc.2018.02.045","volume":"26","author":"Sovi\u0107 I.","year":"2018","unstructured":"Sovi\u0107 I.; Jambon S.; Kraljevi\u0107 Paveli\u0107 S.; Markova-Car E.; Ili\u0107 N.; Depauw S.; David-Cordonnier M.H.; Karminski-Zamola G.; Syn-thesis, antitumor activity and DNA binding features of benzothiazolyl and benzimidazolyl substituted isoindolines. Bioorg Med Chem 2018,26(8),1950-1960","journal-title":"Bioorg Med Chem"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"102978","DOI":"10.1016\/j.bioorg.2019.102978","volume":"89","author":"Philoppes J.N.","year":"2019","unstructured":"Philoppes J.N.; Lamie P.F.; Design and synthesis of new benzoxazole\/benzothiazole-phthalimide hybrids as antitumor-apoptotic agents. Bioorg Chem 2019,89,102978","journal-title":"Bioorg Chem"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"130595","DOI":"10.1016\/j.molstruc.2021.130595","volume":"1240","author":"El-Meguid E.A.A.","year":"2021","unstructured":"El-Meguid E.A.A.; Moustafa G.O.; Awad H.M.; Zaki E.R.; Nossier E.S.; Novel benzothiazole hybrids targeting EGFR: Design, synthe-sis, biological evaluation and molecular docking studies. J Mol Struct 2021,1240,130595","journal-title":"J Mol Struct"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.ejmech.2018.06.049","volume":"155","author":"Alt\u0131ntop M.D.","year":"2018","unstructured":"Alt\u0131ntop M.D.; Sever B.; Akal\u0131n \u00c7ift\u00e7i G.; Turan-Zitouni G.; Kaplanc\u0131kl\u0131 Z.A.; \u00d6zdemir A.; Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential AKT and FAK inhibitors. Eur J Med Chem 2018,155,905-924","journal-title":"Eur J Med Chem"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3892\/ijo.2015.3306","volume":"48","author":"Nitulescu G.M.","year":"2016","unstructured":"Nitulescu G.M.; Margina D.; Juzenas P.; Peng Q.; Olaru O.T.; Saloustros E.; Fenga C.; Spandidos D.A.; Libra M.; Tsatsakis A.M.; AKT inhibitors in cancer treatment: The long journey from drug discovery to clinical use. (Review) Int J Oncol 2016,48(3),869-885","journal-title":"Int J Oncol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1134\/S107036321812023X","volume":"88","author":"Kumar P.S.","year":"2018","unstructured":"Kumar P.S.; Umadevi P.; Novel bis (1,2,4-oxadiazolyl) fused thiazole derivatives: Synthesis and anticancer activity. Russ J Gen Chem 2018,88(12),2611-2615","journal-title":"Russ J Gen Chem"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1039\/C8MD00395E","volume":"10","author":"Sankara Rao N.","year":"2018","unstructured":"Sankara Rao N.; Nagesh N.; Lakshma Nayak V.; Sunkari S.; Tokala R.; Kiranmai G.; Regur P.; Shankaraiah N.; Kamal A.; Design and synthesis of DNA-intercalative naphthalimide-benzothiazole\/cinnamide derivatives: Cytotoxicity evaluation and topoisomerase-II\u03b1 inhibition. MedChemComm 2018,10(1),72-79","journal-title":"MedChemComm"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3390\/molecules23051054","volume":"23","author":"Osmaniye D.","year":"2018","unstructured":"Osmaniye D.; Levent S.; Karaduman A.B.; Ilg\u0131n S.; \u00d6zkay Y.; Kaplanc\u0131kl\u0131 Z.A.; Synthesis of new benzothiazole acylhydrazones as anticancer agents. Molecules 2018,23(5),1054","journal-title":"Molecules"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1021\/acsmedchemlett.0c00100","volume":"11","author":"Pugh K.W.","year":"2020","unstructured":"Pugh K.W.; Zhang Z.; Wang J.; Xu X.; Munthali V.; Zuo A.; Blagg B.S.J.; From bacteria to cancer: A benzothiazole-based DNA gyrase B inhibitor redesigned for Hsp90 C-terminal inhibition. ACS Med Chem Lett 2020,11(8),1535-1538","journal-title":"ACS Med Chem Lett"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc1716","volume":"5","author":"Whitesell L.","year":"2005","unstructured":"Whitesell L.; Lindquist S.L.; HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005,5(10),761-772","journal-title":"Nat Rev Cancer"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"82330","DOI":"10.1039\/C6RA17235K","volume":"6","author":"Terracciano S.","year":"2016","unstructured":"Terracciano S.; Foglia A.; Chini M.G.; Vaccaro M.C.; Russo A.; Dal Piaz F.; Saturnino C.; Riccio R.; Bifulco G.; Bruno I.; New dihy-dropyrimidin-2 (1H)-one based Hsp90 C-terminal inhibitors. RSC Advances 2016,6(85),82330-82340","journal-title":"RSC Advances"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1111\/febs.12147","volume":"280","author":"Barrott J.J.","year":"2013","unstructured":"Barrott J.J.; Haystead T.A.; Hsp90, an unlikely ally in the war on cancer. FEBS J 2013,280(6),1381-1396","journal-title":"FEBS J"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.4155\/fmc.14.89","volume":"6","author":"Hall J.A.","year":"2014","unstructured":"Hall J.A.; Forsberg L.K.; Blagg B.S.J.; Alternative approaches to Hsp90 modulation for the treatment of cancer. Future Med Chem 2014,6(14),1587-1605","journal-title":"Future Med Chem"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"Hanahan D.","year":"2011","unstructured":"Hanahan D.; Weinberg R.A.; Hallmarks of cancer: The next generation. Cell 2011,144(5),646-674","journal-title":"Cell"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ejmech.2019.01.004","volume":"165","author":"Liu Q.Q.","year":"2019","unstructured":"Liu Q.Q.; Lu K.; Zhu H.M.; Kong S.L.; Yuan J.M.; Zhang G.H.; Chen N.Y.; Gu C.X.; Pan C.X.; Mo D.L.; Su G.F.; Identification of 3-(benzazol-2-yl)quinoxaline derivatives as potent anticancer compounds: Privileged structure-based design, synthesis, and bioactive evaluation in vitro and in vivo. Eur J Med Chem 2019,165,293-308","journal-title":"Eur J Med Chem"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"104481","DOI":"10.1016\/j.bioorg.2020.104481","volume":"106","author":"Tokala R.","year":"2021","unstructured":"Tokala R.; Mahajan S.; Kiranmai G.; Sigalapalli D.K.; Sana S.; John S.E.; Nagesh N.; Shankaraiah N.; Development of \u03b2-carboline-benzothiazole hybrids via carboxamide formation as cytotoxic agents: DNA intercalative topoisomerase II\u03b1 inhibition and apoptosis in-duction. Bioorg Chem 2021,106,104481","journal-title":"Bioorg Chem"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1016\/j.bmcl.2019.06.020","volume":"29","author":"Ammazzalorso A.","year":"2019","unstructured":"Ammazzalorso A.; De Lellis L.; Florio R.; Laghezza A.; De Filippis B.; Fantacuzzi M.; Giampietro L.; Maccallini C.; Tortorella P.; Veschi S.; Loiodice F.; Cama A.; Amoroso R.; Synthesis of novel benzothiazole amides: Evaluation of PPAR activity and anti-proliferative effects in paraganglioma, pancreatic and colorectal cancer cell lines. Bioorg Med Chem Lett 2019,29(16),2302-2306","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.ejphar.2015.09.027","volume":"765","author":"Gao J.","year":"2015","unstructured":"Gao J.; Yuan S.; Jin J.; Shi J.; Hou Y.; PPAR\u03b1 regulates tumor progression, foe or friend? Eur J Pharmacol 2015,765,560-564","journal-title":"Eur J Pharmacol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"44635","DOI":"10.18632\/oncotarget.5988","volume":"6","author":"Gao J.","year":"2015","unstructured":"Gao J.; Liu Q.; Xu Y.; Gong X.; Zhang R.; Zhou C.; Su Z.; Jin J.; Shi H.; Shi J.; Hou Y.; PPAR\u03b1 induces cell apoptosis by destruct-ing Bcl2. Oncotarget 2015,6(42),44635-44642","journal-title":"Oncotarget"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"e1900675","DOI":"10.1002\/cbdv.201900675","volume":"17","author":"Ceylan M.","year":"2020","unstructured":"Ceylan M.; Erkan S.; Yaglioglu A.S.; Akdogan Uremis N.; Ko\u00e7 E.; Antiproliferative evaluation of some 2\u2010[2\u2010(2\u2010phenylethenyl)\u2010cyclopent\u20103\u2010en\u20101\u2010yl]\u20101,3\u2010benzothiazoles: DFT and molecular docking study. Chem Biodivers 2020,17(4),e1900675","journal-title":"Chem Biodivers"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.21873\/anticanres.12091","volume":"37","author":"Uremis N.","year":"2017","unstructured":"Uremis N.; Uremis M.M.; Tolun F.I.; Ceylan M.; Doganer A.; Kurt A.H.; Synthesis of 2-substituted benzothiazole derivatives and their in vitro anticancer effects and antioxidant activities against pancreatic cancer cells. Anticancer Res 2017,37(11),6381-6389","journal-title":"Anticancer Res"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"190","DOI":"10.25135\/acg.oc.18.17.02.009","volume":"10","author":"Uremis M.M.","year":"2017","unstructured":"Uremis M.M.; Yaglioglu A.S.; Budak Y.; Ceylan M.; Synthesis, characterization, in vitro antiproliferative and cytotoxicity effects of a new class of 2-((1R, 2S)-2-((E)-4-substitutedstyryl)cyclooctyl)benzo[d]thiazole derivatives. Org Commun 2017,10(3),190-200","journal-title":"Org Commun"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"e1900178","DOI":"10.1002\/ardp.201900178","volume":"352","author":"El-Helby A.A.","year":"2019","unstructured":"El-Helby A.A.; Sakr H.; Eissa I.H.; Al-Karmalawy A.A.; El-Adl K.; Benzoxazole\/benzothiazole-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations. Arch Pharm (Weinheim) 2019,352(12),e1900178","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrm.2016.87","volume":"17","author":"Simons M.","year":"2016","unstructured":"Simons M.; Gordon E.; Claesson-Welsh L.; Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol 2016,17(10),611-625","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12885-019-5322-0","volume":"19","author":"Lian L.","year":"2019","unstructured":"Lian L.; Li X.L.; Xu M.D.; Li X.M.; Wu M.Y.; Zhang Y.; Tao M.; Li W.; Shen X.M.; Zhou C.; Jiang M.; VEGFR2 promotes tumor-igenesis and metastasis in a pro-angiogenic-independent way in gastric cancer. BMC Cancer 2019,19(1),183","journal-title":"BMC Cancer"}],"container-title":["Current Organic Synthesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570179419666220330001036","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/202800\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570179419666220330001036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T12:02:41Z","timestamp":1669032161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/202800\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":131,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570179419666220330001036","relation":{},"ISSN":["1570-1794"],"issn-type":[{"value":"1570-1794","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}